Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

IGI Laboratories, Inc. was founded in 1977 and is headquartered in Buena, New Jersey. IGI Laboratories, Inc. engages in the development, manufacture, filling, and packaging of topical, semi solid, and liquid products for pharmaceutical, cosmeceutical, and cosmetic companies. The company focuses on the commercialization of its licensed Novasome encapsulation technology for skin care/treatment products. It licenses the Novasome encapsulation technology from Novavax, Inc. for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals, as well as the processes for making the same. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008.

InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

Healthpoint, Ltd. company was founded in 1992 and is based in Fort Worth, Texas. Healthpoint, Ltd. operates as a subsidiary of DFB Pharmaceuticals, Inc. Healthpoint, Ltd., a specialty pharmaceutical company, develops and markets pharmaceutical and medical products for the treatment of chronic wounds. It focuses on the prevention and treatment of diseased and traumatized skin and related soft tissue. The company provides tissue management products, which includes sterile enzymatic debriding ointment, extracellular matrix-based wound product, bacteriostatic dressing, ointment for perineal wounds, papain-urea debriding ointment, doxepin hydrocloride cream, moisturizing dermal wound cleanser, hydrogel wound dressing, odor eliminator, powder for superficial skin infections caused by yeast, and protectant for intact and injured skin, as well as healing, debriding, and deodorizing ointment. It also offers surgical products, such as brush-free scrubbing products, surgical scrubs, waterless scrubs, healthcare personnel handwash and rub, hand and body antiseptic, one-step prep solutions, and topical anesthetic sprays. The company serves healthcare market, which includes nurses, physicians, surgeons, nursing homes, home health agencies, and office-based practices. It distributes its products through drug wholesalers and medical/surgical distributors.

Reliv' International, Inc. was founded in 1984 and is headquartered in Chesterfield, Missouri. Reliv' International, Inc. is a developer, manufacturer and marketer of a line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. The Company offers 16 nutritional supplements and a line of seven skin care products. Its core line of nutritional supplements, which represented 64.5% of net sales, during the year ended December 31, 2008, includes four products: Reliv Classic and Reliv NOW, two basic nutritional supplements containing a full and balanced blend of vitamins, minerals, proteins and herbs; Innergize!, an isotonic sports supplement in three flavors, and FibRestore, a high-fiber and antioxidant supplement. The Company’s product line includes nutritional supplements that address basic nutrition, specific wellness needs, weight management and sports nutrition.

BMP Sunstone Corporation, formerly Beijing Med-Pharm Corporation, is a specialty pharmaceutical company with over-the-counter (OTC) manufacturing, marketing and distribution based in China. Through its subsidiary, Sunstone (Tangshan) Pharmaceutical Co., Ltd. (Sunstone) it manufactures, markets and distributes OTC products in China. Through Beijing Medpharm Co. Ltd. (BMP China), Beijing Wanwei Pharmaceutical Co., Ltd., (Wanwei), and Shanghai Rongheng Pharmaceutical Company (Rongheng), it offers to foreign and domestic pharmaceutical manufacturers in China, services focused primarily on marketing and promotional services and distribution services. It operates in three segments: branded OTC segment, which includes the operations of Sunstone, Pharmaceutical Distribution segment, which includes the operations of Wanwei and Rongheng and Licensed Products segment, which includes the operations of BMP China. On July 4, 2008, it completed the acquisition of 63.3% interest in Rongheng.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

BioZone Laboratories provides contract development, manufacturing, and marketing of OTC drugs, cosmetics, and supplements. It's OTC products include acne, anti-itch, cough and cold, and wound care products. Supplements include antioxidants, minerals, and vitamins. BioZone also makes more than 20 different kinds of lotions, creams, and ointments. The company has several delivery systems under patent, including LipoSpray, a respiratory drug delivery system, that is designed to deliver the active pharmaceuticals using very tiny encapsulations, liposomes, that allow for more sustained delivery. BioZone was founded by President Daniel Fisher and EVP Brian Keller.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.